These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25735977)
1. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells. Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977 [TBL] [Abstract][Full Text] [Related]
2. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells. Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679 [TBL] [Abstract][Full Text] [Related]
3. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969 [TBL] [Abstract][Full Text] [Related]
4. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170 [TBL] [Abstract][Full Text] [Related]
5. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552 [TBL] [Abstract][Full Text] [Related]
6. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835 [TBL] [Abstract][Full Text] [Related]
7. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling. Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771 [TBL] [Abstract][Full Text] [Related]
8. SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells. Yang Q; Sun K; Gao T; Gao Y; Yang Y; Li Z; Zuo D Mol Carcinog; 2024 Nov; 63(11):2133-2144. PubMed ID: 39078281 [TBL] [Abstract][Full Text] [Related]
9. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing. Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157 [TBL] [Abstract][Full Text] [Related]
10. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566 [TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415 [TBL] [Abstract][Full Text] [Related]
12. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242 [TBL] [Abstract][Full Text] [Related]
13. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer. Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576 [TBL] [Abstract][Full Text] [Related]
14. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371 [TBL] [Abstract][Full Text] [Related]
15. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216 [TBL] [Abstract][Full Text] [Related]
16. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892 [TBL] [Abstract][Full Text] [Related]
17. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910 [TBL] [Abstract][Full Text] [Related]
18. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412 [TBL] [Abstract][Full Text] [Related]
19. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. Penzel R; Schirmacher P; Warth A J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607 [TBL] [Abstract][Full Text] [Related]
20. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Tan S; Sun D; Pu W; Gou Q; Guo C; Gong Y; Li J; Wei YQ; Liu L; Zhao Y; Peng Y Mol Cancer; 2018 Sep; 17(1):138. PubMed ID: 30236141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]